 NEW YORK and LONDON, June 23, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc NASDAQ: TLSA, LSE: TILS, Tiziana or the Company, a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization CRO, to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 COVID-19 and pulmonary inflammation. 